VIVOBIOTBiotechnology
Vivo Bio Tech Ltd — Profit & Loss Statement
₹21.05
+0.00%
Vivo Bio Tech Ltd Profit & Loss Statement (Annual)
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Tax Effect Of Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Tax Rate For Calcs | 0.17 | 0.38 | 0.30 | 0.30 | — |
| Normalized EBITDA | 25.31 Cr | 21.13 Cr | 21.54 Cr | 15.91 Cr | — |
| Total Unusual Items | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Total Unusual Items Excluding Goodwill | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income From Continuing Operation Net Minority Interest | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Reconciled Depreciation | 8.96 Cr | 9.13 Cr | 9.27 Cr | 7.45 Cr | — |
| Reconciled Cost Of Revenue | 5.79 Cr | 3.85 Cr | 6.77 Cr | 11.44 Cr | — |
| EBITDA | 25.31 Cr | 21.13 Cr | 21.54 Cr | 15.91 Cr | — |
| EBIT | 16.30 Cr | 11.84 Cr | 12.27 Cr | 8.47 Cr | — |
| Net Interest Income | -7.50 Cr | -7.78 Cr | -7.95 Cr | -4.17 Cr | — |
| Interest Expense | 7.50 Cr | 7.78 Cr | 7.65 Cr | 3.99 Cr | — |
| Normalized Income | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Net Income From Continuing And Discontinued Operation | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Total Expenses | 35.18 Cr | 33.65 Cr | 39.66 Cr | 42.65 Cr | — |
| Diluted NI Availto Com Stockholders | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Net Income Common Stockholders | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Otherunder Preferred Stock Dividend | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Minority Interests | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Income Including Noncontrolling Interests | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Net Income Extraordinary | 0.00 | 0.00 | 0.00 | — | — |
| Net Income Discontinuous Operations | 0.00 | 0.00 | 0.00 | — | — |
| Net Income Continuous Operations | 7.28 Cr | 2.53 Cr | 2.65 Cr | 2.20 Cr | — |
| Tax Provision | 1.51 Cr | 1.53 Cr | 1.97 Cr | 2.27 Cr | — |
| Pretax Income | 8.79 Cr | 4.06 Cr | 4.62 Cr | 4.47 Cr | — |
| Other Non Operating Income Expenses | 4.80 Cr | 0.04 Cr | 0.04 Cr | 0.10 Cr | — |
| Special Income Charges | 0.00 | 0.00 | 0.00 | 0.00 | — |
| Net Non Operating Interest Income Expense | -7.50 Cr | -7.78 Cr | -7.95 Cr | -4.17 Cr | — |
| Interest Expense Non Operating | 7.50 Cr | 7.78 Cr | 7.65 Cr | 3.99 Cr | — |
| Operating Income | 11.49 Cr | 11.80 Cr | 12.57 Cr | 8.74 Cr | — |
| Operating Expense | 29.39 Cr | 29.80 Cr | 32.89 Cr | 31.21 Cr | — |
| Depreciation And Amortization In Income Statement | 9.02 Cr | 9.29 Cr | 9.27 Cr | 7.45 Cr | — |
| Depreciation Income Statement | 9.02 Cr | 9.29 Cr | 9.27 Cr | 7.45 Cr | — |
| Selling General And Administration | 8.23 Cr | 9.83 Cr | 7.18 Cr | 7.53 Cr | — |
| General And Administrative Expense | 8.23 Cr | 9.83 Cr | 6.91 Cr | 7.41 Cr | — |
| Gross Profit | 40.88 Cr | 41.60 Cr | 45.46 Cr | 39.95 Cr | — |
| Cost Of Revenue | 5.79 Cr | 3.85 Cr | 6.77 Cr | 11.44 Cr | — |
| Total Revenue | 46.67 Cr | 45.45 Cr | 52.23 Cr | 51.39 Cr | — |
| Operating Revenue | 46.67 Cr | 45.45 Cr | 52.23 Cr | 51.39 Cr | — |
| Interest Income | — | 0.04 Cr | 0.04 Cr | 0.10 Cr | 0.08 Cr |
| Rent Expense Supplemental | — | 0.43 Cr | 0.96 Cr | 4.13 Cr | 4.22 Cr |
| Diluted Average Shares | — | 1.67 Cr | 1.48 Cr | 1.42 Cr | 1.36 Cr |
| Basic Average Shares | — | 1.49 Cr | 1.48 Cr | 1.41 Cr | 1.34 Cr |
| Diluted EPS | — | 1.51 | 1.78 | 1.56 | 4.19 |
| Basic EPS | — | 1.70 | 1.78 | 1.56 | 4.23 |
| Total Other Finance Cost | — | 0.17 Cr | 0.33 Cr | 0.28 Cr | 0.14 Cr |
| Interest Income Non Operating | — | 0.04 Cr | 0.04 Cr | 0.10 Cr | 0.08 Cr |
| Other Operating Expenses | — | 3.05 Cr | 1.95 Cr | 2.68 Cr | 2.00 Cr |
| Selling And Marketing Expense | — | 0.28 Cr | 0.28 Cr | 0.12 Cr | 3.66 Cr |
| Rent And Landing Fees | — | 0.43 Cr | 0.96 Cr | 4.13 Cr | 4.22 Cr |
| Write Off | — | — | — | — | 0.00 |
All figures in ₹ Crores. Source: NSE/BSE filings via Bull Run.
More on Vivo Bio Tech Ltd
Data from NSE/BSE public filings. Educational purposes only. Bull Run is not SEBI-registered. Not investment advice.